IMAB - I-Mab - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-3.111B

Cash

3.449B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.75%

Institutional Own.

64.05%

Qtr Updated

12/31/22

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TJ202 (Felzartamab) (CD38 mAb) Details Multiple myeloma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TJ101 (Eftansomatropin alfa) Details Pediatric growth hormone deficiency Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lemzoparlimab Details High risk myelodysplastic syndromes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TJ301 (Olamkicept) (gp130 IL-6 inhibitor) Details Ulcerative colitis, Autoimmune disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Felzartamab (MOR202) (CD38) Details IgA nephropathy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TJ107 (Efineptakin alfa) (IL-7) Details Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
uliledlimab (TJD5) (TJ004309) (anti-CD73) (+ atezolizumab (TECENTRIQ®)) Details Cancer, Non-small cell lung carcinoma Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MOR210 (TJ210) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enoblituzumab (TJ271) + Pembrolizumab Details Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.